Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Maier
Christiane
C
Institut für Humangenetik, Universität Ulm, Ulm, Germany. christiane.maier@uni-ulm.de
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics* / Q000378:metabolism; D042944:Cholestenone 5 alpha-Reductase / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D017211:Treatment Failure
D004791:Enzyme Inhibitors; D042944:Cholestenone 5 alpha-Reductase; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase